Kymera Therapeutics KYMR 深 沪
已收盘 09-04 16:00:00 美东时间
117.39
+0.110
+0.09%
华盛通- 最 高118.28
- 今 开115.09
- 成交量 37.86万股
- 最 低 112.77
- 昨 收 117.28
- 总市值 97.61亿
- 52周最高 130.05
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 46.25
- 委 比 -86.67%
- 总股本 8315.06万
- 历史最高 130.05
- 量 比 0.59
- 振 幅 4.70%
- 历史最低 9.60
- 每 手 1
- 风险率 20.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Kymera Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several upcoming investor events, including the Wells Fargo Healthcare Conference, Citi Biopharma Summit, H.C. Wainwright Global Investment Conference, Morgan Stanley Global Healthcare Conference, and Stifel Immunology Forum. Live webcasts and replays will be available on the company’s website. Kymera focuses on developing oral small molecule degraders...
09-02 20:01
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
The Trend Catcher | Comml Svcs-Staffing Continues to Strengthen, YYGH Surges 68%; EXEL, MCO, MNST (Rating 95+) Nearing Breakouts
Markets were flat as PCE inflation matched core expectations, while Machinery and Staffing sectors led gains, and Cre8, Expion360, and YY Group posted sharp rallies.
08-26 23:00
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139
Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.
08-06 22:00
财报速睇 | Kymera Therapeutics 2026财年Q2营收0.65亿美元，同比增长466.4%；归母净利润亏损0.61亿美元，同比亏损缩窄20.1%
华盛资讯8月5日讯，Kymera Therapeutics公布2026财年Q2业绩，公司Q2营收0.65亿美元，同比增长466.4%，归母净利润亏损0.61亿美元，同比亏损缩窄20.1%。
08-05 19:41
Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share from the same period last year. The company reported quarterly sales of $65.000 mi...
08-05 19:04
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
